by Alison Bass | Feb 7, 2012 | antidepressants, clinical trials, conflicts of interest, FDA, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct
I was hesitant to weigh in at first when I learned that Brown University’s School of Medicine had decided not to pressure a psychiatric journal to retract the seriously flawed Paxil study that I wrote about in Side Effects. After all, Brown has been covering up...
by Alison Bass | Jan 26, 2012 | antidepressants, conflicts of interest, continuing medical education, drug marketing, ghostwriting, pharmaceutical industry, university industry collaboration
The Obama administration recently made it clear that it will require drug companies to disclose the payments they make to doctors for research, consulting, speaking, travel and entertainment under the new health care law — see the New York Times. Large numbers...
by Alison Bass | Jan 18, 2012 | antipsychotic drugs, conflicts of interest, drug marketing, expert testimony, media coverage, pharmaceutical industry, whistleblowing
Allen Jones, the whistleblower in an ongoing landmark trial against the pharmaceutical giant Johnson & Johnson, was very much on my mind this past weekend. I was participating in a workshop to develop curriculum to teach college students about the importance of...
by Alison Bass | Jan 5, 2012 | Uncategorized
In preparing for the holidays, you may have missed the French scandal over the defective artificial breasts implanted in hundreds of thousands of women. According to NPR, an estimated 400,000 women worldwide have received the faulty implants, and 30,000 women in...
by Alison Bass | Dec 26, 2011 | Uncategorized
A few weeks before Thanksgiving, my husband, a hospice social worker, was told that his hours were being cut back from full to part-time. The explanation given to him, a six-year employee with solid performance reviews, was that the hospice’s census had declined...